Histological assessment of non-alcoholic fatty liver disease

Histopathology

Volumn 49, Issue 5, 2006, Pages 450-465

  Hubscher S G ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Cirrhosis; Fatty liver; Grading and staging; Insulin resistance; Liver biopsy; Metabolic syndrome; Non alcoholic; Steatohepatitis; Steatosis

Indexed keywords

BILIARY TRACT DISEASE; CHRONIC LIVER DISEASE; CLINICAL ASSESSMENT; DISEASE CLASSIFICATION; FATTY LIVER; HEPATITIS; HISTOLOGY; HISTOPATHOLOGY; HUMAN; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER INJURY; METABOLIC SYNDROME X; MORPHOLOGY; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; REVIEW; STEATOSIS;

BIOPSY; CHRONIC DISEASE; FATTY LIVER; HUMANS; LIVER CIRRHOSIS; LIVER DISEASES, ALCOHOLIC; METABOLIC SYNDROME X;

EID: 33750312176     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2006.02416.x     Document Type: Review

References (155)

1. Diehl AM, Li ZP, Lin HZ, Yang SQ. Cytokines and the pathogenesis of non-alcoholic steatohepatitis. Gut 2005; 54; 303-306.
2. Reid AE. Nonalcoholic steatohepatitis. Gastroenterology 2001; 121; 710-723.
3. Ramesh S, Sanyal AJ. Evaluation and management of nonalcoholic steatohepatitis. J. Hepatol. 2005; 42 (Suppl.); S2-12.
4. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome-a new worldwide definition. Lancet 2005; 366; 1059-1062.
5. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365; 1415-1428.
6. Adams LA, Angulo P. Recent concepts in non-alcoholic fatty liver disease. Diabet. Med. 2005; 22; 1129-1133.
7. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005; 42; 44-52.
8. Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology 2002; 122; 1649-1657.
9. Dam-Larsen S, Franzmann M, Andersen IB et al. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut 2004; 53; 750-755.
10. Cortez-Pinto H, de Moura MC, Day CP. Non-alcoholic steatohepatitis: from cell biology to clinical practice. J. Hepatol. 2006; 44; 197-208.
11. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin. Proc. 1980; 55; 434-438.
12. Skelly MM, James PD, Ryder SD. Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology. J. Hepatol. 2001; 35; 195-199.
13. de Ledinghen V, Combes M, Trouette H et al. Should a liver biopsy be done in patients with subclinical chronically elevated transaminases? Eur. J. Gastroenterol. Hepatol. 2004; 16; 879-883.
14. Madan K, Batra Y, Panda SK et al. Role of polymerase chain reaction and liver biopsy in the evaluation of patients with asymptomatic transaminitis: implications in diagnostic approach. J. Gastroenterol. Hepatol. 2004; 19; 1291-1299.
15. Torezan-Filho MA, Alves VA, Neto CA, Fernandes HS, Strauss E. Clinical significance of elevated alanine aminotransferase in blood donors: a follow-up study. Liver Int. 2004; 24; 575-581.
16. Mofrad P, Contos MJ, Haque M et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003; 37; 1286-1292.
17. Sorrentino P, Tarantino G, Conca P et al. Silent non-alcoholic fatty liver disease - a clinical-histological study. J. Hepatol. 2004; 41; 751-757.
18. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999; 29; 664-669.
19. Poonawala A, Nair SP, Thuluvath PJ. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology 2000; 32; 689-692.
20. Bugianesi E, Leone N, Vanni E et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123; 134-140.
21. Ratziu V, Bonyhay L, Di MV et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 2002; 35; 1485-1493.
22. Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 2002; 36; 1349-1354.
23. Shimada M, Hashimoto E, Taniai M et al. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J. Hepatol. 2002; 37; 154-160.
24. Bugianesi E. Review article: steatosis, the metabolic syndrome and cancer. Aliment. Pharmacol. Ther. 2005; 22 (Suppl. 2); 40-43.
25. Spaulding L, Trainer T, Janiec D. Prevalence of non-alcoholic steatohepatitis in morbidly obese subjects undergoing gastric bypass. Obes. Surg. 2003; 13; 347-349.
26. Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 2005; 42; 987-1000.
27. Day CP, James OF. Steatohepatitis. a tale of two 'hits'? Gastroenterology 1998; 114; 842-845.
28. Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin. Liver Dis. 2001; 21; 27-41.
29. Day CP. Non-alcoholic steatohepatitis (NASH): where are we now and where are we going? Gut 2002; 50; 585-588.
30. Younossi ZM, Diehl AM, Ong JP. Nonalcoholic fatty liver disease: an agenda for clinical research. Hepatology 2002; 35; 746-752.
31. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003; 37; 1202-1219.
32. Choudhury J, Sanyal AJ. Insulin resistance and the pathogenesis of nonalcoholic fatty liver disease. Clin. Liver Dis. 2004; 8; 575-594.
33. Pessayre D, Fromenty B. NASH: a mitochondrial disease. J. Hepatol. 2005; 42; 928-940.
34. Samuel VT, Liu ZX, Qu X et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J. Biol. Chem. 2004; 279; 32345-32353.
35. Schattenberg JM, Wang Y, Singh R, Rigoli RM, Czaja MJ. Hepatocyte CYP2E1 overexpression and steatohepatitis lead to impaired hepatic insulin signaling. J. Biol. Chem. 2005; 280; 9887-9894.
36. Sanyal AJ, Campbell-Sargent C, Mirshahi F et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120; 1183-1192.
37. Le TH, Caldwell SH, Redick JA et al. The zonal distribution of megamitochondria with crystalline inclusions in nonalcoholic steatohepatitis. Hepatology 2004; 39; 1423-1429.
38. Albano E, Mottaran E, Vidali M et al. Immune response towards lipid peroxidation products as a predictor of progression of non-alcoholic fatty liver disease to advanced fibrosis. Gut 2005; 54; 987-993.
39. Kaser S, Moschen A, Cayon A et al. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut 2005; 54; 117-121.
40. Marra F, Aleffi S, Bertolani C, Petrai I, Vizzutti F. Review article: the pathogenesis of fibrosis in non-alcoholic steatohepatitis. Aliment. Pharmacol. Ther. 2005; 22 (Suppl. 2); 44-47.
41. Wanless IR, Shiota K. The pathogenesis of nonalcoholic steatohepatitis and other fatty liver diseases: a four-step model including the role of lipid release and hepatic venular obstruction in the progression to cirrhosis. Semin. Liver Dis. 2004; 24; 99-106.
42. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am. J. Gastroenterol. 1999; 94; 2467-2474.
43. Castera L, Hezode C, Roudot-Thoraval F et al. Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies. Gut 2003; 52; 288-292.
44. Fartoux L, Chazouilleres O, Wendum D, Poupon R, Serfaty L. Impact of steatosis on progression of fibrosis in patients with mild hepatitis C. Hepatology 2005; 41; 82-87.
45. Nonomura A, Enomoto Y, Takeda M et al. Clinical and pathological features of non-alcoholic steatohepatitis. Hepatol. Res. 2005; 33; 116-121.
46. Banner BF, Savas L, Zivny J, Tortorelli K, Bonkovsky HL. Ubiquitin as a marker of cell injury in nonalcoholic steatohepatitis. Am. J. Clin. Pathol. 2000; 114; 860-866.
47. Zatloukal K, Stumptner C, Fuchsbichler A et al. p62 Is a common component of cytoplasmic inclusions in protein aggregation diseases. Am. J. Pathol. 2002; 160; 255-263.
48. Feldstein AE, Canbay A, Angulo P et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003; 125; 437-443.
49. Ribeiro PS, Cortez-Pinto H, Sola S et al. Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients. Am. J. Gastroenterol. 2004; 99; 1708-1717.
50. Guicciardi ME, Gores GJ. Apoptosis: a mechanism of acute and chronic liver injury. Gut 2005; 54; 1024-1033.
51. Feldstein AE, Canbay A, Guicciardi ME, Higuchi H, Bronk SF, Gores GJ. Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice. J. Hepatol. 2003; 39; 978-983.
52. Walsh MJ, Vanags DM, Clouston AD et al. Steatosis and liver cell apoptosis in chronic hepatitis C: a mechanism for increased liver injury. Hepatology 2004; 39; 1230-1238.
53. Caldwell SH, Swerdlow RH, Khan EM et al. Mitochondrial abnormalities in non-alcoholic steatohepatitis. J. Hepatol. 1999; 31; 430-434.
54. Lefkowitch JH, Haythe JH, Regent N. Kupffer cell aggregation and perivenular distribution in steatohepatitis. Mod. Pathol. 2002; 15; 699-704.
55. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990; 11; 74-80.
56. Caldwell SH, Crespo DM. The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease. J. Hepatol. 2004; 40; 578-584.
57. Bullock RE, Zaitoun AM, Aithal GP, Ryder SD, Beckingham IJ, Lobo DN. Association of non-alcoholic steatohepatitis without significant fibrosis with hepatocellular carcinoma. J. Hepatol. 2004; 41; 685-686.
58. Davila JA, Morgan RO, Shaib Y, McGlynn KA, El Serag HB. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 2005; 54; 533-539.
59. Yang S, Koteish A, Lin H et al. Oval cells compensate for damage and replicative senescence of mature hepatocytes in mice with fatty liver disease. Hepatology 2004; 39; 403-411.
60. Libbrecht L, Desmet V, Van Damme B, Roskams T. The immunohistochemical phenotype of dysplastic foci in human liver: correlation with putative progenitor cells. J. Hepatol. 2000; 33; 76-84.
61. Libbrecht L, Desmet V, Roskams T. Preneoplastic lesions in human hepatocarcinogenesis. Liver Int. 2005; 25; 16-27.
62. Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin. Liver Dis. 2001; 21; 3-16.
63. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001; 121; 91-100.
64. Abrams GA, Kunde SS, Lazenby AJ, Clements RH. Portal fibrosis and hepatic steatosis in morbidly obese subjects: a spectrum of nonalcoholic fatty liver disease. Hepatology 2004; 40; 475-483.
65. Dixon JB, Bhathal PS, Hughes NR, O'Brien PE. Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss. Hepatology 2004; 39; 1647-1654.
66. Adams LA, Lindor KD, Angulo P. The prevalence of autoantibodies and autoimmune hepatitis in patients with nonalcoholic fatty liver disease. Am. J. Gastroenterol. 2004; 99; 1316-1320.
67. Cotler SJ, Kanji K, Keshavarzian A, Jensen DM, Jakate S. Prevalence and significance of autoantibodies in patients with non-alcoholic steatohepatitis. J. Clin. Gastroenterol. 2004; 38; 801-804.
68. Alvarez F, Berg PA, Bianchi FB et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J. Hepatol. 1999; 31; 929-938.
69. Czaja AJ, Homburger HA. Autoantibodies in liver disease. Gastroenterology 2001; 120; 239-249.
70. Ayata G, Gordon FD, Lewis WD et al. Cryptogenic cirrhosis: clinicopathologic findings at and after liver transplantation. Hum. Pathol. 2002; 33; 1098-1104.
71. Roskams T, Yang SQ, Koteish A et al. Oxidative stress and oval cell accumulation in mice and humans with alcoholic and nonalcoholic fatty liver disease. Am. J. Pathol. 2003; 163; 1301-1311.
72. Clouston AD, Powell EE, Walsh MJ, Richardson MM, Demetris AJ, Jonsson JR. Fibrosis correlates with a ductular reaction in hepatitis C: roles of impaired replication, progenitor cells and steatosis. Hepatology 2005; 41; 809-818.
73. Roskams T, Desmet V. Ductular reaction and its diagnostic significance. Semin. Diagn. Pathol. 1998; 15; 259-269.
74. Sorrentino P, Tarantino G, Perrella A, Micheli P, Perrella O, Conca P. A clinical-morphological study on cholestatic presentation of nonalcoholic fatty liver disease. Dig. Dis. Sci. 2005; 50; 1130-1135.
75. Gramlich T, Kleiner DE, McCullough AJ, Matteoni CA, Boparai N, Younossi ZM. Pathologic features associated with fibrosis in nonalcoholic fatty liver disease. Hum. Pathol. 2004; 35; 196-199.
76. Younossi ZM, Gramlich T, Bacon BR et al. Hepatic iron and nonalcoholic fatty liver disease. Hepatology 1999; 30; 847-850.
77. Chitturi S, Weltman M, Farrell GC et al. HFE mutations, hepatic iron, and fibrosis: ethnic-specific association of NASH with C282Y but not with fibrotic severity. Hepatology 2002; 36; 142-149.
78. Chitturi S, George J. Interaction of iron, insulin resistance, and nonalcoholic steatohepatitis. Curr. Gastroenterol. Rep. 2003; 5; 18-25.
79. Bugianesi E, Manzini P, D'Antico S et al. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology 2004; 39; 179-187.
80. Powell EE, Jonsson JR, Clouston AD. Steatosis: co-factor in other liver diseases. Hepatology 2005; 42; 5-13.
81. Roberts EA. Steatohepatitis in children. Best. Pract. Res. Clin. Gastroenterol. 2002; 16; 749-765.
82. Roberts EA. Nonalcoholic steatohepatitis in children. Curr. Gastroenterol. Rep. 2003; 5; 253-259.
83. Marion AW, Baker AJ, Dhawan A. Fatty liver disease in children. Arch. Dis. Child. 2004; 89; 648-652.
84. Roberts EA. Non-alcoholic fatty liver disease (NAFLD) in children. Front Biosci. 2005; 10; 2306-2318.
85. Lavine JE, Schwimmer JB. Nonalcoholic fatty liver disease in the pediatric population. Clin. Liver Dis. 2004; 8; 549-558.
86. Nanda K. Non-alcoholic steatohepatitis in children. Pediatr. Transplant. 2004; 8; 613-618.
87. Baldridge AD, Perez-Atayde AR, Graeme-Cook F, Higgins L, Lavine JE. Idiopathic steatohepatitis in childhood: a multicenter retrospective study. J. Pediatr. 1995; 127; 700-704.
88. Manton ND, Lipsett J, Moore DJ, Davidson GP, Bourne AJ, Couper RT. Non-alcoholic steatohepatitis in children and adolescents. Med. J. Aust. 2000; 173; 476-479.
89. Rashid M, Roberts EA. Nonalcoholic steatohepatitis in children. J. Pediatr. Gastroenterol. Nutr. 2000; 30; 48-53.
90. Molleston JP, White F, Teckman J, Fitzgerald JF. Obese children with steatohepatitis can develop cirrhosis in childhood. Am. J. Gastroenterol. 2002; 97; 2460-2462.
91. Schwimmer JB, Behling C, Newbury R et al. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology 2005; 42; 641-649.
92. Sorbi D, McGill DB, Thistle JL, Therneau TM, Henry J, Lindor KD. An assessment of the role of liver biopsies in asymptomatic patients with chronic liver test abnormalities. Am. J. Gastroenterol. 2000; 95; 3206-3210.
93. Saadeh S, Younossi ZM, Remer EM et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123; 745-750.
94. Joy D, Thava VR, Scott BB. Diagnosis of fatty liver disease: is biopsy necessary? Eur. J. Gastroenterol. Hepatol. 2003; 15; 539-543.
95. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30; 1356-1362.
96. Chitturi S, Abeygunasekera S, Farrell GC et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002; 35; 373-379.
97. Pagano G, Pacini G, Musso G et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology 2002; 35; 367-372.
98. Lee RG. Nonalcoholic steatohepatitis: tightening the morphological screws on a hepatic rambler. Hepatology 1995; 21; 1742-1743.
99. Younossi ZM, Gramlich T, Liu YC et al. Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations. Mod. Pathol. 1998; 11; 560-565.
100. Kleiner DE, Brunt EM, Van Natta M et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41; 1313-1321.
101. Brunt EM, Neuschwander-Tetri BA, Oliver D, Wehmeier KR, Bacon BR. Nonalcoholic steatohepatitis: histologic features and clinical correlations with 30 blinded biopsy specimens. Hum. Pathol. 2004; 35; 1070-1082.
102. Brunt EM. Pathology of nonalcoholic steatohepatitis. Hepatol. Res. 2005; 33; 68-71.
103. Teli MR, James OF, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 1995; 22; 1714-1719.
104. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116; 1413-1419.
105. Saksena S. Natural history and determinants of disease progression in non-alcoholic fatty liver disease: good and bad news. Hepatology 2003; 38; 232A.
106. Harrison SA, Torgerson S, Hayashi PH. The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am. J. Gastroenterol. 2003; 98; 2042-2047.
107. McCullough AJ. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin. Liver Dis. 2004; 8; 521-533.
108. Fassio E, Alvarez E, Dominguez N, Landeira G, Longo C. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology 2004; 40; 820-826.
109. Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J. Hepatol. 2005; 42; 132-138.
110. Diehl AM. Obesity and alcoholic liver disease. Alcohol 2004; 34; 81-87.
111. Diehl AM, Goodman Z, Ishak KG. Alcohollike liver disease in nonalcoholics. A clinical and histologic comparison with alcohol-induced liver injury. Gastroenterology 1988; 95; 1056-1062.
112. Itoh S, Yougel T, Kawagoe K. Comparison between nonalcoholic steatohepatitis and alcoholic hepatitis. Am. J. Gastroenterol. 1987; 82; 650-654.
113. Contos MJ, Cales W, Sterling RK et al. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl. 2001; 7; 363-373.
114. Brunt EM. Alcoholic and nonalcoholic steatohepatitis. Clin. Liver Dis. 2002; 6; 399-420.
115. Kuwabara H, Yoshii Y, Mori H et al. Nonalcoholic steatohepatitis-related cirrhosis with subacute liver failure: an autopsy case. Dig. Dis. Sci. 2003; 48; 1668-1670.
116. Nakano M, Fukusato T. Histological study on comparison between NASH and ALD. Hepatol. Res. 2005; 33; 110-115.
117. Sanderson SO, Smyrk TC. The use of protein tyrosine phosphatase 1B and insulin receptor immunostains to differentiate nonalcoholic from alcoholic steatohepatitis in liver biopsy specimens. Am. J. Clin. Pathol. 2005; 123; 503-509.
118. Farrell GC. Drug-induced steatohepatitis. In Drug-induced liver disease. Edinburgh: Churchill Livingstone 1994; 431-438.
119. Clouston AD, Powell EE. Interaction of non-alcoholic fatty liver disease with other liver diseases. Best. Pract. Res. Clin. Gastroenterol. 2002; 16; 767-781.
120. Brunt EM, Ramrakhiani S, Cordes BG et al. Concurrence of histologic features of steatohepatitis with other forms of chronic liver disease. Mod. Pathol. 2003; 16; 49-56.
121. Asselah T, Rubbia-Brandt L, Marcellin P, Negro F. Steatosis in chronic hepatitis C: why does it really matter? Gut 2006; 55; 123-130.
122. Hui JM, Sud A, Farrell GC et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. Gastroenterology 2003; 125; 1695-1704.
123. Narita R, Abe S, Kihara Y, Akiyama T, Tabaru A, Otsuki M. Insulin resistance and insulin secretion in chronic hepatitis C virus infection. J. Hepatol. 2004; 41; 132-138.
124. Lonardo A, Adinolfi LE, Loria P, Carulli N, Ruggiero G, Day CP. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology 2004; 126; 586-597.
125. Zekry A, McHutchison JG, Diehl AM. Insulin resistance and steatosis in hepatitis C virus infection. Gut 2005; 54; 903-906.
126. Rubbia-Brandt L, Quadri R, Abid K et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J. Hepatol. 2000; 33; 106-115.
127. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R., Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33; 1358-1364.
128. Younossi ZM, McCullough AJ, Ong JP et al. Obesity and nonalcoholic fatty liver disease in chronic hepatitis C. J. Clin. Gastroenterol. 2004; 38; 705-709.
129. Rubbia-Brandt L, Fabris P, Paganin S et al. Steatosis affects chronic hepatitis C progression in a genotype specific way. Gut 2004; 53; 406-412.
130. Westin J, Nordlinder H, Lagging M, Norkrans G, Wejstal R. Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. J. Hepatol. 2002; 37; 837-842.
131. Ong JP, Younossi ZM, Speer C, Olano A, Gramlich T, Boparai N. Chronic hepatitis C and superimposed nonalcoholic fatty liver disease. Liver 2001; 21; 266-271.
132. Monto A, Alonzo J, Watson JJ, Grunfeld C, Wright TL. Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. Hepatology 2002; 36; 729-736.
133. Ramalho F. Hepatitis C virus infection and liver steatosis. Antiviral Res. 2003; 60; 125-127.
134. Poynard T, Ratziu V, McHutchison J et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003; 38; 75-85.
135. Patton HM, Patel K, Behling C et al. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J. Hepatol. 2004; 40; 484-490.
136. Ortiz V, Berenguer M, Rayon JM, Carrasco D, Berenguer J. Contribution of obesity to hepatitis C-related fibrosis progression. Am. J. Gastroenterol. 2002; 97; 2408-2414.
137. Wyatt J, Baker H, Prasad P, Gong YY, Millson C. Steatosis and fibrosis in patients with chronic hepatitis C. J. Clin. Pathol. 2004; 57; 402-406.
138. Bressler BL, Guindi M, Tomlinson G, Heathcote J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003; 38; 639-644.
139. Clouston AD, Jonsson JR, Purdie DM et al. Steatosis and chronic hepatitis C: analysis of fibrosis and stellate cell activation. J. Hepatol. 2001; 34; 314-320.
140. Hickman IJ, Clouston AD, Macdonald GA et al. Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut 2002; 51; 89-94.
141. Gordon A, McLean CA, Pedersen JS, Bailey MJ, Roberts SK. Hepatic steatosis in chronic hepatitis B and C: predictors, distribution and effect on fibrosis. J. Hepatol. 2005; 43; 38-44.
142. Langman G, Hall PM, Todd G. Role of non-alcoholic steatohepatitis in methotrexate-induced liver injury. J. Gastroenterol. Hepatol. 2001; 16; 1395-1401.
143. Bruno S, Maisonneuve P, Castellana P et al. Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial. BMJ 2005; 330; 932.
144. Ratziu V, Poynard T. NASH: a hidden and silent fibroser finally revealed? J. Hepatol. 2005; 42; 12-14.
145. Ratziu V, Giral P, Charlotte F et al. Liver fibrosis in overweight patients. Gastroenterology 2000; 118; 1117-1123.
146. Ong JP, Younossi ZM. Nonalcoholic fatty liver disease (NAFLD) - two decades later: are we smarter about its natural history? Am. J. Gastroenterol. 2003; 98; 1915-1917.
147. Promrat K, Lutchman G, Uwaifo GI et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004; 39; 188-196.
148. Mendler MH, Kanel G, Govindarajan S. Proposal for a histological scoring and grading system for non-alcoholic fatty liver disease. Liver Int. 2005; 25; 294-304.
149. Franzen LE, Ekstedt M, Kechagias S, Bodin L. Semiquantitative evaluation overestimates the degree of steatosis in liver biopsies: a comparison to stereological point counting. Mod. Pathol. 2005; 18; 912-916.
150. Marsman H, Matsushita T, Dierkhising R et al. Assessment of donor liver steatosis: pathologist or automated software? Hum. Pathol. 2004; 35; 430-435.
151. Merriman RB, Ferrell LD, Patti MG et al. Histologic correlation of paired right lobe and left lobe liver biopsies in morbidly obese individuals with suspected non alcoholic fatty liver disease. Hepatology 2003; 38; 232A.
152. Mendez P, Regev A, Molina E et al. Sampling error and reliability of liver biopsy in patients with non-alcoholic fatty liver disease (NAFLD). Hepatology 2003; 38; 673A.
153. Janiec DJ, Jacobson ER, Freeth A, Spaulding L, Blaszyk H. Histologic variation of grade and stage of non-alcoholic fatty liver disease in liver biopsies. Obes. Surg. 2005; 15; 497-501.
154. Ratziu V, Charlotte F, Heurtier A et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005; 128; 1898-1906.
155. Goldstein NS, Hastah F, Galan MV, Gordon SC. Fibrosis heterogeneity in nonalcoholic steatohepatitis and hepatitis C virus needle core biopsy specimens. Am. J. Clin. Pathol. 2005; 123; 382-387.